

=> d his

(FILE 'HOME' ENTERED AT 17:05:57 ON 23 NOV 1998)

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR,
AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, BIOTECHDS, CABA,
CANCERLIT, CAPLUS, CEABA, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL,
...' ENTERED AT 17:06:30 ON 23 NOV 1998

E CHU H/IN

SEA E3-E12

0* FILE ADISALERTS
0* FILE ADISINSIGHT
0* FILE AGRICOLA
0* FILE AIDSLINE
0* FILE ANABSTR
0* FILE AQUASCI
0* FILE BIOBUSINESS
0* FILE BIOSIS
5 FILE BIOTECHABS
5 FILE BIOTECHDS
0* FILE CANCERLIT
1 FILE CAPLUS
0* FILE CEABA
0* FILE CEN
0* FILE CIN
0* FILE CONFSCI
7 FILE DDFB
0* FILE DDFU
42 FILE DGENE
7 FILE DRUGB
0* FILE DRUGLAUNCH
0* FILE DRUGMONOG2
0* FILE DRUGNL
0* FILE DRUGU
0* FILE EMBAL
0* FILE EMBASE
1 FILE FSTA
0* FILE GENBANK
0* FILE HEALSAFE
0* FILE KOSMET
0* FILE LIFESCI
0* FILE MEDLINE
0* FILE NIOSHTIC
0* FILE NTIS
0* FILE OCEAN
0* FILE PHAR
0* FILE PHIC
0* FILE PHIN
0* FILE PROMT
0* FILE SCISEARCH
0* FILE TOXLINE
0* FILE TOXLIT
67 FILE WPIDS
67 FILE WPINDEX
5 FILE APIPAT
60 FILE DPCI

7 FILE JROPATFULL
3 FILE NPADOC
1 FILE PATDPA
1 FILE PATOSDE
38 FILE PATOSEP
23 FILE PATOSWO
2 FILE PIRA
6 FILE RAPRA
3 FILE TULSA
3 FILE TULSA2

L1

QUE ("CHU H"/IN OR "CHU H C"/IN OR "CHU H D"/IN OR "CHU H

SEA L1 AND STREPTOCOCCUS EQUI

0* FILE ADISALERTS
0* FILE ADISINSIGHT
0* FILE AGRICOLA
0* FILE AIDSLINE
0* FILE ANABSTR
0* FILE AQUASCI
0* FILE BIOBUSINESS
0* FILE BIOSIS
0* FILE CANCERLIT
0* FILE CEABA
0* FILE CEN
0* FILE CIN
0* FILE CONFSCI
0* FILE DDFU
0* FILE DRUGLAUNCH
0* FILE DRUGMONOG2
0* FILE DRUGNL
0* FILE DRUGU
0* FILE EMBAL
0* FILE EMBASE
0* FILE GENBANK
0* FILE HEALSAFE
0* FILE KOSMET
0* FILE LIFESCI
0* FILE MEDLINE
0* FILE NIOSHTIC
0* FILE NTIS
0* FILE OCEAN
0* FILE PHAR
0* FILE PHIC
0* FILE PHIN
0* FILE PROMT
0* FILE SCISEARCH
0* FILE TOXLINE
0* FILE TOXLIT

L2

QUE L1 AND STREPTOCOCCUS EQUI

=> s attenuatedstreptococcus equi
<-----User Break----->

u

=> s attenuated streptococcus equi

25 FILES SEARCHED...

1 FILE IFIPAT

40 FILES SEARCHED...

1 FILE USPATFULL

1 FILE EUROPATFULL

53 FILES SEARCHED...

3 FILES HAVE ONE OR MORE ANSWERS, 65 FILES SEARCHED IN STNINDEX

L1 QUE ATTENUATED STREPTOCOCCUS EQUI

=> d his

(FILE 'HOME' ENTERED AT 15:49:38 ON 23 NOV 1998)

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR,
AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, BIOTECHDS, CABA,
CANCERLIT, CAPLUS, CEABA, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL,
...' ENTERED AT 15:49:52 ON 23 NOV 1998

SEA STREPTOCOCCUS EQUI

116 FILE AGRICOLA
SEA ATTENUATEDSTREPTOCOCCUS EQUI

SEA ATTENUATED STREPTOCOCCUS EQUI

1 FILE IFIPAT
1 FILE USPATFULL
1 FILE EUROPATFULL
L1 QUE ATTENUATED STREPTOCOCCUS EQUI

SEA STREPTOCOCCUS EQUI

116 FILE AGRICOLA
1 FILE AIDSLINE
1 FILE AQUASCI
12 FILE BIOBUSINESS
184 FILE BIOSIS
56 FILE BIOTECHABS
56 FILE BIOTECHDS
276 FILE CABA
2 FILE CANCERLIT
110 FILE CAPLUS
4 FILE CEABA
1 FILE CIN
3 FILE CONFSCI
10 FILE DGENE
1 FILE DRUGU
90 FILE EMBASE
36 FILE GENBANK
18 FILE IFIPAT
18 FILE JICST-EPLUS
71 FILE LIFESCI
133 FILE MEDLINE
1 FILE PHAR
14 FILE PHIN
1 FILE PROMT
100 FILE SCISEARCH
10 FILE TOXLINE
17 FILE TOXLIT
54 FILE USPATFULL
36 FILE WPIDS
36 FILE WPINDEX
14 FILE DPCI
8 FILE EUROPATFULL
49 FILE INPADOC
16 FILE JAPIO
4 FILE PATDPA

L2

2 FILE PATOSDE
5 FILE PATOSEP
2 FILE PATOSWO

QUE STREPTOCOCCUS EQUI

FILE 'CABA, BIOSIS, MEDLINE, AGRICOLA, CAPLUS, SCISEARCH, EMBASE,
LIFESCI, BIOTECHDS, USPATFULL, INPADOC, GENBANK, WPIDS, IFIPAT,
JICST-EPLUS, TOXLIT, JAPIO, PHIN, DPCI, BIOBUSINESS, DGENE,
TOXLINE, EUROPATFULL, PATOSEP, CEABA, PATDPA, CONFSCI, CANCERLIT,
...' ENTERED AT 15:54:43 ON 23 NOV 1998

L3 1476 S STREPTOCOCCUS EQUI
L4 828 DUP REM L3 (648 DUPLICATES REMOVED)
L5 2 S L4(10A)ATTENUATED
L6 0 S L5 AND ADJUVANT
L7 0 S L5 AND SAPONIN
L8 128 S L4 AND VACCINE
L9 2 S 8L AND SAPONIN
L10 2 S L8 AND SAPONIN

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

Pat. No. 4,944,942

The . . . methyl salicylate the preferred range is between 1 and 4 weight percent. Finally, the formulation may contain a recognized vaccine **adjuvant** such as aluminum hydroxide gel or those taught in U.S. Pat. No. 3,919,411, preferably at levels between about 5 and. . . for the former type and levels between about 5 and 20% being preferred for the latter type. An especially preferred **adjuvant** is based on the polyacrylic acid cross linked with polyallyl sucrose sold as Carbopol 934P combined with polyoxyethylene sorbitan mono-oleate. . .

> d his

(FILE 'USPAT' ENTERED AT 15:40:11 ON 23 NOV 1998)

L1 54 S STREPTOCOCCUS EQUI
L2 1 S L1 AND SAPONIN
L3 23 S L1 AND VACCINE
L4 0 S ATTENUATED STREPTOCOCCUS EQUI
L5 1 S ATTENUATED STREPTOCOCCUS EQUI
L6 0 S L5 AND ADJUVANT
L7 0 S L5 AND INTERFERON
L8 1 S L5
L9 0 S L5 AND SAPONIN

=> s 18

31405 ATTENUATED
6273 STREPTOCOCCUS
8108 EQUI
L10 1 ATTENUATED STREPTOCOCCUS EQUI
(ATTENUATED(W) STREPTOCOCCUS(W) EQUI)

=> d 1 kwic

US PAT NO: 4,788,059 [IMAGE AVAILABLE]

L10: 1 of 1

SUMMARY:

BSUM(10)

It is an invention to provide a method of immunizing equines against virulent strains of Streptococcus equi by inoculating the equine with an **attenuated Streptococcus equi** organism.

CLAIMS:

CLMS(1)

I . . .

A vaccine effective in protecting equines against infection by virulent strains of Streptococcus equi comprising an immunizing dosage of an **attenuated Streptococcus equi** organism rendered avirulent while retaining its antigenicity through prolonged culturing in the presence of acriflavine hydrochloride.

<-----User Break----->

d his

(FILE 'USPAT' ENTERED AT 16:19:37 ON 23 NOV 1998)

L1	0 S STREPTOCOCCUS EQUI AND AVIREULENT
L2	10 S STREPTOCOCCUS EQUI AND AVIRULENT
L3	3 S L2 AND ADJUVANT
L4	0 S TREPTOCOCCUS EQUI
L5	54 S STREPTOCOCCUS EQUI
L6	10 S L5 AND ADJUVANT

L3 ANSWER 14 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1987-04225 BIOTECHDS
TI **Vaccine** for protection against **Streptococcus**

equi;

containing **avirulent** mutant obtained from parent strain by
mutagenesis

PA Cornell-Res.Found.

PI WO 8700436 29 Jan 1987

AI WO 1986-US1460 14 Jul 1986

PRAI US 1985-754613 12 Jul 1985

DT Patent

LA English

OS WPI: 1987-037174 [05]

AB A **vaccine** for protecting horses against **Streptococcus**

equi (causing the disease strangles) comprises an

avirulent strain of **S. equi** which stimulates

an antibody response in the nasopharyngeal mucosa. The new strain is

made

by mutation of a virulent strain and retains a protein providing an
M-protein fragment of mol.wt. 41,000. This fragment stimulates

formation

of IgG and IgA antibodies similar to those found in animals which have
recovered from infection with virulent **S. equi**. The

avirulent strain is non-encapsulated, and is especially **S**

. equi 709-27 (ATCC 53186). The **vaccine** may be given

intranasally or orally. 709-27 is developed from the highly virulent

strain CF32 (ATCC 53185) by nitrosoguanidine mutagenesis followed by
screening for loss of virulence and for ability to protect mice. The

vaccine provides efficient protection without any side-effects in

Jemany

4748019

US6004802

195

L3 ANSWER 16 OF 48 CABA COPYRIGHT 1999 CABI
AN 86:39843 CABA
DN 862276553
TI The protective response of the horse to an **avirulent** strain of
Streptococcus equi
AU Timoney, J. F.; Galan, J. E.; Y. Kimura [EDITOR]; others [EDITOR]
CS Coll. Vet. Med., Cornell Univ., Ithaca, NY 14853, USA.
SO Recent advances in streptococci and streptococcal diseases, (1985) pp.
294-295. Proceedings of the IXth Lancefield International Symposium on
Streptococci and Streptococcal Diseases, Japan, September 1984. 7 ref.
Publisher: Reedbooks Ltd. Chertsey
CY United Kingdom
DT Conference Article
LA English
AB **Avirulent** strain 709-27 of **S. equi**,
developed as a **live vaccine** for nasal immunization
against strangles, led to the production of IgA and IgG antibodies in the
nasal mucosa, directed against a protein of 41 000 molecular weight.
Serum
antibod

L3 ANSWER 6 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1999-09279 BIOTECHDS
TI A **Streptococcus equi vaccine**;
live attenuated **Streptococcus**
equi vaccine, produced from **S.**
equi culture, used to **vaccinate** against strangles in
horses
PA Akzo-Nobel
LO Arnheim, The Netherlands.
PI JP 11100329 13 Apr 1999
AI JP 1998-210514 27 Jul 1998
PRAI EP 1997-202925 24 Sep 1997; EP 1997-202365 29 Jul 1997
DT Patent
LA Japanese
OS WPI: 1999-296484 [25]
AB A **live, attenuated Streptococcus**
equi bacterium, especially **S. equi** TW928
(CBS813.95), used for the production of an optionally lyophilized
vaccine, is claimed. The **vaccine** is used to prevent
S. equi infection, following systemic administration,
particularly by i.m. or s.m., particularly lip s.m. administration. The
vaccine may optionally also include an adjuvant, an antigen, or
another **attenuated** pathogen. The pathogen is preferably a
Potomac fever agent, **Rhodococcus equi**, **Clostridium tetani**, **Mycobacterium**
pseudomallei, **Streptococcus zooepidemicus**, vesicular stomatitis virus,
Borna virus, horse influenza virus, African horse sickness virus, horse
arteritis virus, equid herpes virus 1-4, infectious anemia virus, horse
encephalomyelitis virus, or Japanese type-B encephalitis virus.
S. equi TW928 is **attenuated** by conventional
techniques, and kept in a refrigerator, or a buffer containing glycerin
at -70 deg. In an example, horse with no history of strangles were
inoculated with the **vaccine**. Symptoms resulting from
subsequent challenge with **S. equi** resulted in 98%
decreased symptoms. (7pp)

EP 1997
changed
EP 894500
3 Feb 99.

L3 ANSWER 3 OF 48 BIOSIS COPYRIGHT 1999 BIOSIS
 AN 1995:484962 BIOSIS
 DN PREV199598499262
 TI An assessment of mucosal immunisation in protection against
Streptococcus equi ('Strangles') infections in horses.
 AU Wallace, Fiona J. (1); Emery, Julie D.; Cripps, Allan W.; Husband, Alan
 J.
 CS (1) Dep. Pathol., Univ. Newcastle, Level 4, David Maddison Build., Royal
 Newcastle Hosp., Newcastle, N.S.W. 2300 Australia
 SO Veterinary Immunology and Immunopathology, (1995) Vol. 48, No. 1-2, pp.
 139-154.
 ISSN: 0165-2427.
 DT Article
 LA English
 AB The ability of mucosally administered antigen to provide protection
 against **Streptococcus equi** ('Strangles') infections in
 horses was examined. First, an enzyme linked immunosorbent assay (ELISA)
 was developed to detect the immune status of horses to **S.**
equi. This assay was used to select Strangles-naïve horses for the
 study and also to monitor their response to immunisation. Potential
vaccine candidates were: (a) orally administered paraformaldehyde
 killed **S. equi**; (b) intraperitoneally (IP)
 administered paraformaldehyde killed **S. equi** in a
 non-inflammatory adjuvant; (c) orally administered **live**
avirulent S. equi; (d) orally administered
 microencapsulated streptococcal M protein. The latter three preparations
 were first assessed in a rat model, using rate of lung bacterial
 clearance
 following intratracheal inoculation of **live** virulent bacteria as
 an indication of efficacy. Candidates (a) and (b) were then assessed in
 an
 equine model. IP immunisation of horses was shown to effectively induce
 production of specific antibody in mucosal and systemic sites. Four weeks
 after initial immunisation, horses were challenged intranasally with
live virulent **S. equi**. Both groups of
 immunised horses demonstrated partial protection following
vaccination. Of the IP immunised horses, only two out of four
 developed clinical signs of Strangles following **live** challenge.
 The orally immunised horses all developed submandibular abscesses
 containing **S. equi**. However, none of the immunised
 horses became as ill as the control horses in terms of fever, anorexia,
 loss of

L3 ANSWER 25 OF 48 LIFESCI COPYRIGHT 1999 CSA
AN 1999:66133 LIFESCI
TI **Streptococcus equi vaccine**
AU Hartford, O.A.; Foster, T.A.; Jacobs, A.R.H.
CS Provost Fellows & Scholars of the College of the Univ. of the Holy
SO (19990420) . US Patent 5895654; US CLASS: 424/237.1..
DT Patent
FS W2
LA English
SL English
AB The present invention relates to a live attenuated
strain of the bacterium **Streptococcus equi**, a pathogen
causing strangles in horses. The invention also relates to a
vaccine against strangles, methods for the preparation of such a
vaccine and to the use of the strain for the preparation of such a
v

L3 ANSWER 24 OF 48 IFIPAT COPYRIGHT 1999 IFI
 AN 2330060 IFIPAT;IFIUDB;IFICDB
 TI PROTECTION OF EQUINES AGAINST **STREPTOCOCCUS EQUI**;
 BACTERIAL **VACCINE**; ADMINISTERING INTRANASALLY OR ORALLY TO
 HORSES
 INF Timoney, John F, Lansing, NY
 IN Timoney John F
 PAF Cornell Research Foundation, Inc, Ithaca, NY
 PA Cornell Research Foundation Inc (20656)
 EXNAM Brown, Johnnie R
 EXNAM Mohamed, Abdel A
 AG Barnard, Ralph R
 PI US 5183659 19930202
 AI US 1988-207320 19880615
 XPD 2 Feb 2010
 RLI US 1985-754613 19850712 CONTINUATION ABANDONED
 FI US 5183659 19930202
 DT UTILITY
 FS CHEMICAL
 CLMN 10
 GI 4 Drawing Sheet(s), 3 Figure(s).
 AB A new bacterial **vaccine** to protect susceptible equine against
S. equi which causes strangles. The **vaccine**
stimulates a nasopharyngeal immune response in a susceptible equine
through the presence of antibody activity in the nasopharyngeal mucus.
The **vaccine** is a **S. equi** strain which
contains an M protein fragment of 41,000 mw and is adapted for
administration to equine either intranasally or orally as a
vaccine. There is described a new strain of **S.**
equi (709-27), a method of making and isolating useful
vaccine strain of **S. equi** bacteria which
stimulates an antibody response in the nasopharyngeal mucosa of the
su

*live nonencapsul.
 atten. S. equi
 No immunoln?*

L3 ANSWER 13 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1989-02559 BIOTECHDS
TI Horse strangles **vaccine**;
preparation by **attenuating Streptococcus**
equi by culture in the presence of acriflavine hydrochloride
PA Coopers-Anim.Health
PI US 4788059 29 Nov 1988
AI US 1985-754909 15 Jul 1985
PRAI US 1985-754909 15 Jul 1985
DT Patent
LA English
OS WPI: 1988-360693 [50]
AB A **vaccine** effective in protecting horses against infection by
virulent strains of **Streptococcus equi** is new.
S. equi is **attenuated** by prolonged (11 wk)
culture in the presence of acriflavine hydrochloride. The culture
medium
may be Todd-Hewitt broth which preferably contains progressively
increasing concentrations of acriflavine hydrochloride (2 ppm-16 ppm).
Also new is a method of immunizing horses against virulent strains of
S. equi which comprises inoculating the horses with
attenuated S. equi, prepared using the new

Timoney is
S.183659

FBAD
Helen Tre Chw

L3 ANSWER 30 OF 48 TOXLIT
AN 1987:44829 TOXLIT
DN CA-106-162558X
TI **Vaccine** for the protection of equines against
streptococcus equi.
AU Timoney JF
SO (1987). PCT Int. Appl. PATENT NO. 87 00436 01/29/87 (Cornell Research
Foundation, Inc.).
CY United States
DT Patent
FS CA
LA English
OS CA 106:162558
EM 198706
AB **S. equi** 709-27, An equine human strain which contains
an M protein fragment of mol. wt. 41,000, is used in a **live**
vaccine to protect equines from strangles caused by **S.**
equi. **S. equi** CF32 was subjected to
nitrosoguanidine mutagenesis and nonencapsulated colonies were screened
for loss of virulence in mice, for protection of horses, and by
immunoblotting for formation of the 41,000-dalton fragment of M protein.
IgA and IgG antibodies in the nasopharyngeal mucus of **vaccinated**
ponies were directed mainly against this M protein fragment, whereas
serum
an